Fresenius Kabi Oncology Limited Company Profile
|
|
Dabur Pharma (DABURPH) is a specialty pharmaceuticals company with a focus on oncology. Earlier a part of Dabur Industries, the company completed the demerger process in December 2003. The non-executive chairman of the company is Mohit Burman and Dr. Anand C. Burman, the managing director.
The fully integrated pharmaceutical business of Dabur Pharma covers the oral and injectable finished dosage forms and active pharmaceutical ingredients and intermediates. Products include anti-cancer drugs like Anastrozole, Oxaliplatin, Zoledronic Acid, etc; drug intermediates like Baccatin III, Epoxy Propoxy Carbazole, etc; calcium regulators like Alendronate Sodium BP. The company has its manufacturing units for finished dosage forms in Bordon (UK) and Baddi (India), while the active pharmaceutical ingredients (APIs) are manufactured in Kalyani (India) and some products come from Dabur India`s Sahibabad facilities.
The company launched Paclitaxel Nanoparticles, an indigenously developed novel drug delivery system (NDDS) and received final approval from US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Epirubicin injection 50mg and 200mg. The company acquired the entire oncology sales and distribution business from its partner Biosciences Co. in Thailand, while its subsidiary Dabrur Oncology Plc. set up Dabur Pharma US, Inc. to handle sales and marketing in US. The company has a 10-year exclusive agreement with Abbott Labs for generics in the US market.
The company has overseas offices in UK, Malaysia, Russia, Thailand and Philippines. Products are available in more than 40 countries across the globe through a marketing network including Asia Pacific, Commonwealth of Independent States, India, Latin America, North America and the European Union. It recently forayed into Pakistan and Turkmenistan.
The registered office is at 3, Factory Road, Adj. Safdarjung Hospital, New Delhi-110029. |
|
FKONCO Intraday Realtime Chart
|
|
